SUBSCRIBE
SUBSCRIBE
News   Policy

U.S. FDA Panel Rejects FDA and Genentech (South SF)'s (JOBS) Xolair Asthma Drug for Children

November 19, 2009 | 
1 min read
Bookmark and Share

Reuters -- Roche and Novartis's asthma drug Xolair should not be approved for children aged 6 to 11, a U.S. advisory panel decided on Wednesday.
Regulatory
Genentech, Inc. Food and Drug Administration (FDA)
MORE ON THIS TOPIC
man pulling each of the opposite ends of a rope in black and white, on a blue background with some blank space on top
Obesity
Novo, Lilly Jostle For Market Lead in Obesity With New Regulatory Efforts
September 16, 2025
 · 
2 min read
 · 
Tristan Manalac
CDC approved vaccines for adults to boost the immu
Vaccines
Kennedy Names New ACIP Members as Panel Quiets COVID-19 Vaccine Developers Ahead of Meeting
September 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Hanging questions.Blue background.
Adcomms
FDA Flip-Flops on Scrapping Adcomms
September 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Stack of coins balancing on seesaw over a bottle of pills.
Tariffs
Trump Carves Tariff Exemptions for Some Pharma Products
September 12, 2025
 · 
2 min read
 · 
Tristan Manalac